Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN RF 5 2 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN RF 5 2 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN-RF 5.2% vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.
Travasol 2.75% with electrolytes in dextrose 10% is a parenteral nutrition solution. Amino acids provide substrate for protein synthesis, dextrose supplies calories, and electrolytes maintain acid-base balance and osmotic equilibrium.
1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 mL to 1000 mL/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.
Intravenous infusion. Dosage depends on caloric and nitrogen requirements, generally 1-3 L per day in adults providing 4.25 g amino acids and 100 g dextrose per liter.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 10–20 minutes, reflecting rapid distribution and metabolism; clinical context: continuous infusion maintains steady state within 30 minutes.
Not applicable as a single entity; components have variable half-lives. Dextrose has elimination half-life of ~2-4 hours; amino acids have variable half-lives based on individual metabolic rates.
Primarily renal; >95% of infused essential amino acids and small peptides are reabsorbed; excess amino acids are deaminated and nitrogen excreted as urea in urine (renal clearance of urea). Biliary/fecal excretion is negligible (<2%).
Renal (primarily as unchanged drug and metabolites). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution